DBV.PA DBV Technologies S.A. (EURONEXT) earnings 25 Mar 2026: watch Viaskin data

DBV.PA stock is trading intraday on EURONEXT at €3.60, following a +6.20% move as markets price the company’s Q4 and trial news ahead of results due 25 Mar 2026. Volume is 1,017,683 shares so far, below the three‑month average. Investors will focus on VIASKIN Phase 3 signals and the company’s Q4 metrics when DBV reports after European hours, which could trigger volatile intraday swings in Europe in EUR.

DBV.PA stock: Earnings timing and intraday catalysts

DBV.PA stock has an earnings announcement scheduled for 25 Mar 2026 at 16:30 UTC. Market attention is on Viaskin efficacy readouts and any updated regulatory guidance that could affect near‑term commercial planning. The company was added to the CAC Mid 60 and SBF 120 on 23 Mar 2026, a visibility boost that may increase passive flows and intraday liquidity on earnings day.

DBV.PA stock: Clinical progress and news flow

DBV Technologies recently reported that the VIASKIN Peanut Phase 3 VITESSE study met its primary endpoint, a key clinical milestone that underpins revenue potential. Additional Phase 3 data presented at AAAAI and subsequent investor events are the primary non‑financial drivers for the stock.

DBV.PA stock: Financials, valuation and key ratios

On trailing metrics DBV shows negative earnings with EPS -0.90 and PE -3.72, reflecting a clinical‑stage biotech profile. The company’s market cap is about €566.47M and book value per share is €0.55, yielding a price‑to‑book near 7.07. Research and development equals ~79.82% of revenue per the latest TTM ratios, highlighting high R&D intensity that compresses near‑term margins but supports long‑term value if approvals follow.

DBV.PA stock: Technical and intraday price action

Intraday technicals show DBV.PA trading between the day low €3.41 and high €3.68, with an ATR of €0.22 suggesting measurable short‑term volatility. The RSI is 39.31, indicating the stock is not overbought; MACD histogram is negative, so momentum is mixed. Inclusion in wider indices may tighten bid‑ask spreads and increase volume on earnings and trial updates.

DBV.PA stock: Risks, catalysts and analyst context

Key risks include regulatory setbacks, disappointing subgroup data, and cash burn before commercialization. Recent financing in 2025 raised gross proceeds of €166.70M, improving the cash runway but not eliminating execution risk. Catalysts are FDA interactions, pediatric label data, and commercialization plans for VIASKIN Peanut. Analyst coverage is limited but mixed; company rating services show a conservative stance ahead of regulatory clarity.

DBV.PA stock: Meyka AI rating and forecast

Meyka AI rates DBV.PA with a score out of 100: 67.08 (Grade B, HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors. Meyka AI’s forecast model projects a yearly price of €4.16, a quarterly target of €4.91, and a monthly level of €4.31. Compared with the current price (EUR 3.595) those targets imply roughly +15.78%, +36.59%, and +19.89% respectively. Forecasts are model‑based projections and not guarantees.

Final Thoughts

DBV.PA stock enters the 25 Mar 2026 earnings window with clinical wins behind it and clear execution risk ahead. The market is pricing clinical success into the intraday move today; the stock trades near €3.60 with a one‑day volume of 1,017,683 shares. Key drivers will be Q4 financial detail, updated cash runway commentary, and any new regulatory guidance on VIASKIN Peanut. Meyka AI’s forecast model projects a yearly target of €4.16 versus the current price (EUR 3.595), implying an upside of about 15.78%, but the shorter quarterly projection of €4.91 shows larger upside if catalysts land. Investors should weigh the high R&D spend and negative EPS (-0.90) against the program milestones and index inclusion. As an AI‑powered market analysis platform, Meyka AI highlights that DBV’s path depends on trial subgroup clarity and regulatory interactions; intraday moves on 25 Mar 2026 are likely to be pronounced and sentiment driven. Forecasts and grades are model outputs and not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.